Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV-15) compared to PCV-13 in healthy older adults

Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV-15) compared to PCV-13 in healthy older adults

Background: Pneumococcal disease remains a public health priority in adults. Safety and immunogenicity of 2 different formulations of 15-valent pneumococcal conjugate vaccine (PCV15) containing 13 serotypes included in 13-valent pneumococcal conjugate vaccine (PCV13) plus 2 additional serotypes (22F...

Full description

Bibliographic Details
Main Authors: Helen L. Stacey, Jeffrey Rosen, James T. Peterson, Angela Williams-Diaz, Vanita Gakhar, Tina M. Sterling, Camilo J. Acosta, Katrina M. Nolan, Jianing Li, Alison Pedley, Patrice Benner, Chitrananda Abeygunawardana, Michael Kosinski, William J. Smith, Hari Pujar, Luwy K. Musey
Format: Article
Language:English
Published: Taylor & Francis Group 2019-03-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
pneumococcal conjugate vaccine
safety
immunogenicity
Online Access:http://dx.doi.org/10.1080/21645515.2018.1532249

Internet

http://dx.doi.org/10.1080/21645515.2018.1532249

Similar Items